GlassScriptPhysician profile
Austin Ambur
NPI 1649731423
$6,472.44
in general payments reported to CMS, 2019-2025
25 companies · $1,821 in 2025
The $1,821 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.15 · 2020: $155 · 2021: $632 · 2022: $719 · 2023: $1,626 · 2024: $1,500 · 2025: $1,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,766 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,766.28 |
| Education | $181.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.95 | 2020-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $851.56 | 2021-2025 | Tremfya |
| Galderma Laboratories, L.P. | $632.41 | 2024-2025 | Nemluvio |
| Incyte Corporation | $446.93 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $440.10 | 2020-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $435.69 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $389.28 | 2022-2023 | |
| Leo Pharma INC. | $341.02 | 2021-2024 | Adbry |
| Lilly USA, LLC | $314.62 | 2022-2024 | Olumiant, Taltz |
| Genzyme Corporation | $279.55 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $257.26 | 2021-2024 | Winlevi |
| Amgen INC. | $254.71 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $190.34 | 2022-2025 | Cimzia, Bimzelx |
| Dermavant Sciences, INC. | $160.35 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $117.70 | 2023-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $104.68 | 2023 | Tremfya |
| Pfizer INC. | $82.08 | 2023-2025 | |
| Genentech USA, INC. | $57.74 | 2019-2021 | |
| Organogenesis INC. | $46.11 | 2024 | |
| Biofrontera INC. | $41.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2023 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.28 | 2023 | Siliq |
| Revance Therapeutics, INC. | $26.28 | 2024 | Daxxify |
| Mayne Pharma Commercial LLC | $22.39 | 2022 | |
| Merz North America, INC. | $21.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Ambur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.